Vascular Biogenics (NASDAQ: VBLT) recently received a number of ratings updates from brokerages and research firms: 5/15/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 5/7/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 4/29/2022 […]
Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 688,000 shares, a growth of 32.4% from the April 15th total of 519,500 shares. Currently, 1.5% of the company’s shares are short sold. Based […]
Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation […]
Wall Street analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) to report $200,000.00 in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Vascular Biogenics’ earnings. The lowest sales estimate is $190,000.00 and the highest is $200,000.00. Vascular Biogenics reported sales of $190,000.00 during the same quarter last year, which […]